Search

This study identified perceived benefits of animal-assisted therapy (AAT) on anxiety, pain, communication, and cognition among patients waiting for treatment in a large urban cancer center. A convenience sample of 75 patients and five family members (n = 80) waiting for treatment completed a survey about AAT. After giving informed consent, participants were asked to complete questions related to attitudes about offering a complementary therapy dog program in the hospital. Findings indicated that most respondents were very accepting of AAT in the cancer center, with 78 percent indicating that they would like to take part in this complementary therapy. The perceived benefits of AAT included that it would provide a method for positive communication (93 percent), cognitive stimulation (92.3 percent), it would help to pass time more quickly (88.8 percent), it would help people to feel more comfortable at the cancer center (84.8 percent), and it would reduce participants’ pain (71.3 percent) and anxiety (68.4 percent). The association between gender and anxiety produced a statistically meaningful result in this study about predicting subjects’ participation in the program. Ultimately, offering recreational therapy facilitated AAT in cancer center waiting areas may provide benefits for patients and provide a competitive edge to hospitals.

Purpose: This phase II trial of induction irinotecan/gemcitabine followed by twice-weekly gemcitabine and upper abdominal radiation was initiated to determine the activity of this regimen in patients with unresectable pancreatic cancer. Methods: Patients with locally advanced, nonmetastatic adenocarcinoma of the pancreas received 2 cycles of induction irinotecan (100 mg/m 2 IV) and gemcitabine (1000 mg/m 2 IV) on days 1 and 8 of each 3-week cycle. Following the induction, patients without disease progression received gemcitabine administered twice weekly (40 mg/m 2 /day) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy over 5.5 weeks). Results: From April 2000 to August 2003, 20 patients were entered into this study, 17 of whom were evaluable for treatment response. Characteristics included a median age of 67 years (range, 44-87 years) and 14 men (70%). Grades III and IV hematologic toxicity occurred in 25% and 5% of patients respectively and was primarily thrombocytopenia. No grade IV gastrointestinal toxicities or deaths due to therapy were observed. All therapy was completed in 8 patients, 7 patients were removed due to progression, 2 due to toxicity, 2 refused further treatment, and 1 was removed per the treating physician. The median time to progression and median survival was 5.1 months (95% CI, 3.2-6.7) and 8.8 months (95% CI, 6.4-10.1) respectively. Four patients (20%) were alive at 12 and 18 months. Conclusion: Induction irinotecan/gemcitabine followed by twice-weekly gemcitabine and upper abdominal radiation is feasible in patients with locally advanced pancreatic cancer. This regimen, however, has only modest activity and should not be explored further.